Journal
BRITISH JOURNAL OF CANCER
Volume 96, Issue 2, Pages 189-195Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603515
Keywords
angiogenesis inhibitors; biomarkers; clinical trials; dynamic contrast; enhanced magnetic resonance imaging; image analysis
Categories
Funding
- MRC [G0601746] Funding Source: UKRI
- Medical Research Council [G0601746] Funding Source: researchfish
- Medical Research Council [G0601746] Funding Source: Medline
Ask authors/readers for more resources
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T-1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available